Healthcare · Pharmaceuticals: Major
Johnson & Johnson
$284.29 +3.88 (+1.38%) Pre-market $284.24 (+1.37%) ≈ ₹26,681 a share
Key numbers
- Market value
- $684.37B
- P/E (TTM)
- 43.2
- Forward P/E
- 26.1
- EPS (TTM)
- $6.59
- Dividend yield
- 1.89%
- Beta
- 0.20
- Day range
- $281.00 – $285.48
- 52-week range
- $193.07 – $285.48
- Volume
- 1,140,367
- 10-day avg volume
- $7.76M
- Revenue (TTM)
- $99.34B
- EBITDA (TTM)
- $34.54B
- Gross margin
- 67.7%
- Net margin
- 16.2%
- Return on equity
- 20.0%
- Debt / equity
- 54.8%
- Price / sales
- 6.89
- Shares out
- 2.41B
Quarterly results
Results for each quarter
Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.
Revenue and net income
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net income · QoQ (vs last quarter)
Net income · YoY (vs a year ago)
| US$ | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.40B | $21.38B | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B | $25.31B | $25.40B |
| Cost of revenue | $6.80B | $6.51B | $6.87B | $6.96B | $7.13B | $7.36B | $7.63B | $7.30B | $7.97B | $8.11B | $8.05B | $8.10B |
| Gross profit | $14.60B | $14.87B | $15.58B | $15.51B | $15.39B | $14.54B | $16.12B | $16.69B | $16.60B | $15.96B | $17.26B | $17.30B |
| Gross margin | 68.2% | 69.6% | 69.4% | 69.0% | 68.3% | 66.4% | 67.9% | 69.6% | 67.6% | 66.3% | 68.2% | 68.1% |
| Selling, general & admin | $5.81B | $5.26B | $5.68B | $5.48B | $6.45B | $5.11B | $5.89B | $5.92B | $6.75B | $6.03B | $6.43B | $6.29B |
| Interest expense | $22.00M | $155.00M | $270.00M | $193.00M | $137.00M | $204.00M | $308.00M | $245.00M | $214.00M | $272.00M | $281.00M | $217.00M |
| Pre-tax income | $4.83B | $3.71B | $5.75B | $3.34B | $3.89B | $13.63B | $6.49B | $7.49B | $4.97B | $5.99B | $6.75B | $34.00M |
| Income tax | $694.00M | $459.00M | $1.06B | $644.00M | $456.00M | $2.63B | $954.00M | $2.34B | $-150.00M | $755.00M | $1.21B | $-176.00M |
| Net income | $4.05B | $3.26B | $4.69B | $2.69B | $3.43B | $11.00B | $5.54B | $5.15B | $5.12B | $5.24B | $5.53B | $210.00M |
| Net margin | 18.9% | 15.2% | 20.9% | 12.0% | 15.2% | 50.2% | 23.3% | 21.5% | 20.8% | 21.8% | 21.9% | 0.8% |
| EPS (diluted) | $1.67 | $1.34 | $1.93 | $1.11 | — | $4.54 | $2.29 | $2.12 | — | $2.14 | $2.27 | $0.09 |
Income statement
Results for each year
8 fiscal years from the company's 10-K filings with the US SEC.
Revenue, gross profit and net income
Revenue · YoY (vs a year ago)
Net income · YoY (vs a year ago)
EPS (diluted) · YoY (vs a year ago)
| US$ | FY17 | FY18 | FY19 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.89B | $81.58B | $82.06B | $82.58B | $78.74B | $79.99B | $88.82B | $94.19B |
| Revenue growth | — | 13.5% | 0.6% | 0.6% | -4.7% | 1.6% | 11.0% | 6.0% |
| Cost of revenue | $25.44B | $27.09B | $27.56B | $28.43B | $23.40B | $24.60B | $27.47B | $30.26B |
| Gross profit | $50.10B | $54.49B | $54.50B | $54.16B | $55.34B | $55.39B | $61.35B | $63.94B |
| Gross margin | 69.7% | 66.8% | 66.4% | 65.6% | 70.3% | 69.3% | 69.1% | 67.9% |
| Research & development | — | — | — | — | $0 | $0 | $1.84B | $109.00M |
| Selling, general & admin | $20.07B | $22.54B | $22.18B | $22.08B | $20.12B | $20.25B | $22.87B | $23.68B |
| Depreciation & amortisation | $3.75B | $6.93B | $7.01B | $7.23B | $7.39B | $6.97B | $7.34B | $7.50B |
| Interest expense | $726.00M | $1.01B | $318.00M | $201.00M | $183.00M | $276.00M | $755.00M | $971.00M |
| Pre-tax income | $19.80B | $18.00B | $17.33B | $16.50B | $19.18B | $19.36B | $16.69B | $32.58B |
| Income tax | $3.26B | $2.70B | $2.21B | $1.78B | $1.38B | $2.99B | $2.62B | $5.78B |
| Tax rate | 16.5% | 15.0% | 12.7% | 10.8% | 7.2% | 15.4% | 15.7% | 17.7% |
| Net income | $16.54B | $15.30B | $15.12B | $14.71B | $20.88B | $17.94B | $14.07B | $26.80B |
| Net margin | 23.0% | 18.8% | 18.4% | 17.8% | 26.5% | 22.4% | 15.8% | 28.5% |
| EPS (diluted) | $5.93 | $5.61 | $5.63 | $5.51 | $7.81 | $6.73 | $5.79 | $11.03 |
Balance sheet
Assets and debt
At each fiscal year end.
Equity, debt and cash
Shareholders' equity · YoY (vs a year ago)
| US$ | FY17 | FY18 | FY19 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18.97B | $18.11B | $17.31B | $13.99B | $14.49B | $12.89B | $24.11B | $19.71B |
| Short-term investments | $22.94B | $1.58B | $1.98B | $11.20B | $17.12B | $9.39B | $417.00M | $393.00M |
| Current assets | $65.03B | $46.03B | $45.27B | $51.24B | $60.98B | $55.29B | $55.89B | $55.62B |
| Total assets | $141.21B | $152.95B | $157.73B | $174.89B | $182.02B | $187.38B | $180.10B | $199.21B |
| Current liabilities | $26.29B | $31.23B | $35.96B | $42.49B | $45.23B | $55.80B | $50.32B | $54.13B |
| Long-term debt | $22.44B | $27.68B | $26.49B | $32.64B | $29.99B | $26.89B | $30.65B | $39.44B |
| Short-term debt | $1.70B | $2.60B | $1.20B | $1.80B | $2.13B | $1.55B | $1.75B | $2.00B |
| Total debt | $24.14B | $30.28B | $27.69B | $34.43B | $32.12B | $28.44B | $32.40B | $41.44B |
| Total liabilities | $70.79B | $93.20B | $98.26B | $111.62B | $108.00B | $110.57B | $108.61B | $117.67B |
| Shareholders' equity | $70.42B | $59.75B | $59.47B | $63.28B | $74.02B | $76.80B | $71.49B | $81.54B |
| Current ratio | 2.47 | 1.47 | 1.26 | 1.21 | 1.35 | 0.99 | 1.11 | 1.03 |
| Debt / equity | 0.34 | 0.51 | 0.47 | 0.54 | 0.43 | 0.37 | 0.45 | 0.51 |
| Return on equity | 23.5% | 25.6% | 25.4% | 23.3% | 28.2% | 23.4% | 19.7% | 32.9% |
Cash flow
Cash coming in and going out
Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.
Free cash flow and shareholder returns
Operating cash flow · YoY (vs a year ago)
Free cash flow · YoY (vs a year ago)
| US$ | FY17 | FY18 | FY19 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | $18.77B | $22.20B | $23.42B | $23.54B | $23.41B | $21.19B | $24.27B | $24.53B |
| Capital spending | $-3.23B | $-3.67B | $-3.50B | $-3.35B | $-3.65B | $-4.01B | $-4.42B | $-4.83B |
| Free cash flow | $15.54B | $18.53B | $19.92B | $20.19B | $19.76B | $17.19B | $19.84B | $19.70B |
| FCF margin | 21.6% | 22.7% | 24.3% | 24.4% | 25.1% | 21.5% | 22.3% | 20.9% |
| Stock-based pay | $878.00M | $978.00M | $977.00M | $1.01B | $1.14B | $1.14B | $1.18B | $1.35B |
| Cash from investing | $-4.76B | $-3.17B | $-6.19B | $-20.83B | $-8.68B | $-12.37B | $-18.60B | $-23.59B |
| Cash from financing | $-8.55B | $-18.51B | $-18.02B | $-6.12B | $-14.05B | $-8.87B | $-3.13B | $-5.54B |
| Share buybacks | $-8.98B | $-5.87B | $-6.75B | $-3.22B | $-3.46B | $-6.04B | $-2.43B | $-5.95B |
About
About Johnson & Johnson
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.
From Wikipedia (CC BY-SA 4.0).
BRANDS
Company details
- Company name
- Johnson & Johnson
- Ticker
- JNJ
- Exchange
- NYSE
- ISIN
- US4781601046
- SEC CIK
- 0000200406
- Sector
- Healthcare
- Industry
- Pharmaceuticals: Major
- SEC industry (SIC)
- Pharmaceutical Preparations (2834)
- Incorporated in
- New Jersey
- Financial year ends
- 3 January
- Filer type
- Large accelerated filer
- Latest annual report (10-K)
- 11 Feb 2026
- CEO
- Joaquin Duato
- Chair
- Joaquin Duato
- Headquarters
- New Brunswick
- Address
- One Johnson & Johnson Plz, New Brunswick, Nj 08933
- Founded
- 1886
- Employees
- 140,800
- Formerly known as
- Johnson & Johnson Et Al
- Trades in
- US dollars (USD)
- Website
- jnj.com
News
Latest news
From Google News; each link opens the publisher's story.
Peers
Others in Healthcare
Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.